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An acetylation switch controls TDP-43 function
and aggregation propensity
Todd J. Cohen1, Andrew W. Hwang2, Clark R. Restrepo2, Chao-Xing Yuan3, John Q. Trojanowski2
& Virginia M.Y. Lee2
TDP-43 pathology is a disease hallmark that characterizes amyotrophic lateral sclerosis
(ALS) and frontotemporal lobar degeneration (FTLD-TDP). Although a critical role for
TDP-43 as an RNA-binding protein has emerged, the regulation of TDP-43 function is poorly
understood. Here, we identify lysine acetylation as a novel post-translational modification
controlling TDP-43 function and aggregation. We provide evidence that TDP-43 acetylation
impairs RNA binding and promotes accumulation of insoluble, hyper-phosphorylated TDP-43
species that largely resemble pathological inclusions in ALS and FTLD-TDP. Moreover,
biochemical and cell-based assays identify oxidative stress as a signalling cue that promotes
acetylated TDP-43 aggregates that are readily engaged by the cellular defense machinery.
Importantly, acetylated TDP-43 lesions are found in ALS patient spinal cord, indicating that
aberrant TDP-43 acetylation and loss of RNA binding are linked to TDP-43 proteinopathy.
Thus, modulating TDP-43 acetylation represents a plausible strategy to fine-tune TDP-43
activity, which could provide new therapeutic avenues for TDP-43 proteinopathies.
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T
DP-43 is a highly conserved and ubiquitously expressed
nuclear protein that contains two RNA-recognition motifs
(RRMs) involved in RNA and DNA binding, as well as a
glycine-rich C-terminal sequence, which harbours the majority of
the ALS-linked mutations1,2. TDP-43 has diverse cellular roles in
regulating RNA splicing and RNA stability as well as other gene
regulatory functions3–5. High-throughput sequencing approaches
have shown that TDP-43 bindsB6,000 genes and regulates target
RNAs that are essential for proper neuronal development and
synaptic function4–6. In addition to RNA targets, TDP-43 binds
to proximal gene promoters and regulates gene expression of SP-
10 (acrosomal vesicle protein 1) and cdk6 (cyclin-dependent
kinase 6)7–9, suggesting a distinct role in gene transcription.
Studies have also implicated TDP-43 as a stress-responsive RNA-
associated factor required for local translation in the cytoplasm10.
Supporting this finding, TDP-43 is a major component of
neuronal RNA granules and cytoplasmic stress granules (SGs)11–14,
which are active sites of RNA regulation and sorting during
exposure to stress. Thus, the normal physiological functions of
TDP-43 could involve the response to environmental stress via
regulation of downstream genes and RNAs. Although the
identification of TDP-43 target RNAs has been a major focus
recently, the mechanisms that regulate TDP-43 function remain
poorly understood.
TDP-43 is predominantly nuclear localized; however, patho-
logical TDP-43 found in the diseased brain and spinal cord
becomes abnormally aggregated primarily in the cytoplasm,
which has been linked to onset and/or progression of TDP-43
proteinopathy by several pathogenic mechanisms15,16. The
physical presence of cytoplasmic aggregates could exert a toxic
gain of function via impaired vesicle trafficking as well as
cytoskeletal abnormalities17,18. In addition, substantial evidence
indicates that TDP-43 aggregates induce loss of normal nuclear
TDP-43 functions, as nuclear depletion of normally soluble
TDP-43 due to TDP-43 aggregates led to loss of splicing and
transcription activities in cultured cells and transgenic mice19–23.
Pathological TDP-43 is abnormally phosphorylated on
C-terminal serine residues (Ser-403/404 and Ser-409/410) by
multiple kinases24–27 and has emerged as a disease-specific
marker of human TDP-43 proteinopathy16,25,28. Although
phospho-TDP-43 immunoreactivity is valuable as a postmortem
diagnostic tool, the significance of phosphorylation as it relates to
TDP-43 biology is not clear. Indeed, several studies have
indicated that phosphorylation actually prevents rather than
promotes TDP-43 aggregation29,30, suggesting that additional
signalling mechanisms likely exist to modulate TDP-43 functions
and aggregate formation in diseased individuals.
Lysine acetylation has emerged as a major covalent modifica-
tion controlling diverse cellular processes and has been implicated
in Alzheimer’s disease (AD) and other neurodegenerative
disorders31–35. For example, we demonstrated that acetylation
of misfolded tau proteins marks mature neurofibrillary tangles
(NFTs) in AD and related tauopathies and represents a disease-
specific marker of AD pathology31,33,34. In addition to tau, a
global proteomics approach identified B1,750 proteins that are
subject to lysine acetylation, including a distinct subset of
RNA-binding proteins and associated factors36. As TDP-43 is
an RNA-binding protein implicated in ALS, we asked whether
TDP-43 is subject to acetylation, a modification that could
regulate cellular processes linked to ALS pathogenesis. Here, we
show that acetylation occurs on TDP-43 lysine residues within
the RNA-binding domains (RRMs), which functionally abrogates
RNA binding and promotes the accumulation of insoluble TDP-
43 aggregates. Our identification of acetylated TDP-43 lesions
present in ALS patient spinal cord highlights a novel pathological
signature and provides a rationale to explore TDP-43 acetylation
as a potential therapeutic target in ALS and related TDP-43
proteinopathies.
Results
TDP-43 is subject to acetylation at specific lysine residues.
To determine whether TDP-43 is acetylated, co-transfection
experiments were performed with TDP-43 and the acetyl-
transferase Creb-binding protein (CBP), followed by immuno-
precipitation and immunoblotting using a pan-acetyl-lysine
antibody. Ectopically expressed myc-tagged wild-type (WT)
TDP-43 was prominently acetylated only in the presence of CBP
(Fig. 1a and Supplementary Fig. 1). To further confirm TDP-43
acetylation, WT TDP-43 expressing cells were incubated with
[3H]-acetate, and we observed the incorporation of [3H]-labeled
acetyl groups onto TDP-43 by SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE) and autoradiography (Fig. 1b and
Supplementary Fig. 1). Interestingly, mutating the TDP-43
nuclear localization sequence (TDP-43-DNLS) led to increased
TDP-43 acetylation on mislocalization to the cytoplasm (Fig. 1c
and Supplementary Fig. 1), a compartment where TDP-43 forms
inclusions in the diseased human brain and spinal cord. Although
CBP is predominantly nuclear localized, immunofluorescence
analysis indicated that a subpopulation of transfected CBP was
recruited to cytoplasmic TDP-43-DNLS foci (Fig. 1d), thereby
implicating direct CBP-mediated acetylation of TDP-43. There
were no appreciable differences in acetylation among a panel
of ALS-associated TARDBP mutations also directed to the
cytoplasm (Supplementary Fig. 2), consistent with the mild
aggregation phenotype observed for these mutations in cultured
cell lines2.
To identify putative lysine acetylation sites, TDP-43-DNLS was
co-transfected with CBP and subsequently immunoprecipitated
from cell lysates using a TDP-43-specific monoclonal antibody
(clone 171), resulting in enrichment of TDP-43-DNLS that was
readily detected by standard SDS–PAGE and Coomassie stained
gels (Fig. 1e and Supplementary Fig. 3). TDP-43 protein bands
were gel excised, trypsin digested and analysed by mass spectro-
metry using nanoLC/nanospray/MS/MS. On the basis of B75%
sequence coverage of human TDP-43, we identified two major
acetylated sites in the RNA-binding domains (Fig. 1f and
Supplementary Fig. 4); Lys-145 in RRM1, which spans residues
105–169, and Lys-192 immediately adjacent to RRM2, which
spans residues 194–257 (see Fig. 1g for schematic of TDP-43
acetylation sites). Amino-acid mapping onto known crystal
structures of either RRM1 or RRM2 bound to target DNA37,38
showed that acetylation of the Lys-145 and Lys-192 side chains
could potentially interact with and alter nucleic acid binding
(Fig. 1h, Lys residues highlighted in red). Supporting this
possibility, both lysines are adjacent to neighbouring Phe
residues in RRM1 (Phe-147/149) and RRM2 (Phe-229/231),
previously shown to interact directly with nucleic acids39 (Fig. 1h,
Phe residues highlighted in green). To determine whether
Lys-145 and Lys-192 represent major acetylated residues in
TDP-43, we generated a TDP-43-DNLS mutant containing lysine
substitutions (TDP-43-DNLS-2KR). The acetylation-deficient
mutant showed reduced but not completely abrogated
acetylation (Fig. 1i and Supplementary Fig. 5), suggesting
Lys-145 and Lys-192 are dominant sites of acetylation, although
additional acetylated lysines may be present that are not
detectable using this approach.
TDP-43 acetylation enhances aggregate formation. To deter-
mine the consequences of TDP-43 acetylation at these lysine
residues, acetylation mimic (K-Q) and non-mimic (K-R)
mutants were generated and analysed by immunofluorescence
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microscopy. As shown in Fig. 2a, nuclear WT TDP-43 exhibits a
diffuse nucleoplasmic pattern with punctate nuclear bodies as
previously reported23,40. However, a single acetylation mimic
TDP-K145Q, and, more prominently, the double acetylation
mimic TDP-2KQ displayed a severely stippled nuclear
localization in B65% of cells (see Fig. 2b for quantification),
which closely resembled the TDP-4FL RNA-binding-deficient
Phe mutant41, strongly suggesting impaired RNA binding.
Strikingly, targeting acetylation to the cytoplasm using TDP-43-
DNLS containing single or double acetylation mimics showed a
distinct phenotype characterized by cytoplasmic inclusions that
resembled pathological inclusions seen in ALS and other TDP-43
proteinopathies16,28,42 (Fig. 2a,b, B75% aggregates for TDP-43-
DNLS-2KQ).
Acetylation of cytoplasmic TDP-43 using either acetylation-
mimic mutations or co-transfected CBP led to the formation of
bona fide TDP-43 aggregates that are phosphorylated at Ser-409
and Ser-410 (P-409/410), a disease hallmark of TDP-43
pathology28,43 (Fig. 2c). Similarly, solubility assays confirmed
that targeting TDP-43 acetylation mimics to the cytoplasm
increased P-409/410 levels in insoluble fractions (Fig. 2d, lane 6
and Supplementary Fig. 6). Importantly, acetylation-induced
aggregation was not observed with non-mimic K-R
substitutions (Fig. 2d, compare lanes 4–6). Indeed, we attribute
the TDP-43 insolubility to acetylation, as co-transfection of CBP
similarly enhanced the phosphorylation of TDP-43-DNLS that
was recovered in the insoluble fraction (Fig. 2e, lanes 6 and 8 and
Supplementary Fig. 6). Cytoplasmic TDP-43 acetylation similarly
induced aggregation in differentiated Neuro2A cells precluding
any cell-type-specific differences in TDP-43 aggregation
propensity (Supplementary Fig. 7). Thus, these results support
lysine acetylation as a critical determinant of TDP-43 aggregate
formation and highlight distinct aggregation pathologies resulting
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Figure 1 | TDP-43 is subject to lysine acetylation within the RNA-binding domain. (a) QBI-293 cells were transfected with TDP-43 in the presence or
absence of the acetyltransferase CBP and acetylated TDP-43 was evaluated by immunoprecipitation (anti-TDP-43 clone 171) followed by immunoblotting
using an anti-acetylated lysine antibody. (b) Cells transfected with wild-type TDP-43 were pulse-labelled with [3H]-acetate for 2 h followed by
immunoprecipitation and analysis by SDS–PAGE and autoradiography for 2 weeks. Total cellular lysates representing 5% total input were immunoblotted
using anti-TDP-43 and GAPDH antibodies. (c) TDP-43 acetylation assay was performed similar to (a) above using either wild-type TDP-43 or the
cytoplasmic mutant TDP-43-DNLS in the presence of the acetyltransferase CBP. Samples were analysed by immunoprecipitation (top panel) and direct
immunoblotting (bottom panels) using acetylated lysine and total TDP-43 antibodies. (d) Double-labelling immunofluorescence was performed on cells
transfected with CBP and TDP-43-DNLS using anti-HA and anti-myc antibodies, respectively. The merge indicates co-localization of CBP with cytoplasmic-
localized TDP-43. Scale bar, 25mm. (e,f) Cells were transfected with vector alone or TDP-43-DNLS in the absence or presence of CBP and total TDP-43
was immunoprecipitated, separated by SDS–PAGE followed by gel excision, and analysed by mass spectrometry, which identified the K145-acetylated
peptide shown in f. (g) CBP-mediated acetylation of two lysine residues clustered within the RNA-binding regions with significant ion scores and P-values
are shown. (h) Crystal structure analysis of RNA-binding domains RRM1 and RRM2 bound to DNA (Protein Data Bank entries 3D2W and 4IUF) illustrates
Lys-145 and Lys-192 (shown in red) adjacent to critical Phe residues (shown in green) in the context of bound DNA (shown in cyan). (i) Cytoplasmic
TDP-43-DNLS or a comparable construct containing K-R mutations at Lys-145 and Lys-192 (TDP-43-DNLS-2KR) were analysed by immunoblotting in the
presence of CBP and HDAC inhibitors (nicotinamide/TSA) to promote full TDP-43 acetylation. The asterisk (*) indicates acetylated cross-reactive bands
that are unaltered by TDP-43.
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Acetylation-mimics impair TDP-43 RNA-regulatory functions.
Given that the acetylated lysines are located within the RRM
domains, we sought to determine whether TDP-43 acetylation
functionally altered RNA binding. Recombinant full-length TDP-
43 proteins containing acetylation mimic and non-mimic muta-
tions were sequentially extracted from bacteria yielding highly
pure TDP-43 proteins by Coomassie staining (Fig. 3a and
Supplementary Fig. 8). Consistent with high affinity nucleic acid
binding, absorbance readings (A260/280) of WT and TDP-2KR
protein preparations indicated the presence of co-purifying
nucleic acids that were not abundant in preparations of the
TDP-2KQ acetylation-mimic, suggesting a conformational
change induced by charge neutralization (that is, Lys - Gln
substitutions) that abrogated binding to nucleic acids. To assess
the functional consequence of reduced RNA binding to TDP-43,
we utilized a cell-based nuclear CFTR splicing assay in which
TDP-43 expression facilitates exon 9 skipping of a CFTR mini-
gene (Fig. 3b and Supplementary Fig. 8)39,44,45. As expected,
TDP-43 shRNA led to the accumulation of the exon 9 included
(unspliced) transcript and a marked reduction in the spliced/
unspliced ratio, while WT TDP-43 overexpression reversed this
effect by enhancing the exon 9 excluded product (Fig. 3c).
Consistent with a loss of TDP-43 function, the acetylation-mimic
K145Q mutant displayed a partial reduction in the spliced/
unspliced ratio relative to the baseline, and a similar but more
severe loss of function was observed with the RNA-binding-
deficient 4FL mutant, which completely abrogated RNA
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Figure 2 | TDP-43 acetylation promotes pathological features associated with TDP-43 proteinopathies. (a) Double-labelling immunofluorescence
was performed on cells transfected with myc-tagged wild-type TDP-43 or cytoplasmic localized TDP-43-DNLS containing the single acetylation mimic
(K145Q), double mimic (TDP-2KQ) or 4FL RNA-binding-deficient mutations (F147/149/229/231L). White arrows highlight cytoplasmic accumulation
of TDP-43 aggregates. Scale bar, 10mm. (b) Nuclear stippling and cytoplasmic aggregation phenotypes were quantified for all TDP-43 acetylation-mimic
and non-mimic mutants at residues Lys-145 and Lys- 192. Error bars indicate s.e.m., and the single asterisk indicates statistical significance with
P-value o0.05 as measured by two-tailed unpaired t-test with unequal variance from N¼ 3 biological replicates. (c) Cells expressing acetylation-mimic
TDP-43-DNLS (TDP-43-DNLS-2KQ) or CBP-acetylated TDP-43-DNLS were analysed by immunofluorescence microscopy using a phospho-TDP-43
antibody (P-409/410) to mark pathological TDP-43 aggregates. Scale bar, 25mm. (d,e) Soluble (S) and insoluble (I) fractions from cells expressing
acetylation-mimics as well as CBP-mediated acetylated TDP-43 were analysed by immunoblotting using the indicated myc-9E10, TDP-43 (1038),
phospho-TDP-43 (P409/410) or GAPDH antibodies.
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Finally, we utilized a crosslinking immunoprecipitation assay
(CLIP)4,5 to directly assess the RNA-binding activity of acetylated
TDP-43. As expected, WT TDP-43 contains functional
RNA-binding properties5 and physically bound to total cellular
RNAs as determined by TDP-43 gel migration as B50–250 kDa
protein/RNA complexes (Fig. 3d, see TDP-43 bound target RNAs
within the bracket, and Supplementary Fig. 8). However, a single
acetylation-mimic mutant, and more prominently the double
mutant (TDP-K145Q or TDP-2KQ), showed an B50–65%
decrease in RNA binding, a partial loss of function that
approached that observed with the RNA-binding-deficient 4FL
mutant (B 70% decrease), as determined by quantification and
normalization of crosslinked high molecular weight [32P]-labeled
RNAs (Fig. 3e). Thus, a single acetylation-mimic mutation at
Lys-145 within RRM1 is sufficient to significantly impair TDP-43
binding to its cellular mRNA targets.
Arsenite-induced oxidative stress induces TDP-43 acetylation.
Given that TDP-43 has high-affinity RNA binding under normal
conditions46,47, we hypothesized that accessibility to target lysines
would occur more readily following detachment of TDP-43 from
RNAs. Therefore, we employed an oxidative stress paradigm in
which sodium arsenite treatment was previously shown to impair
TDP-43 binding to RNAs, leading to loss of function and
insoluble TDP-43 accumulation11. Supporting stress-induced loss
of TDP-43 function, acute arsenite exposure promoted rapid
accumulation of TDP-43-DNLS into phosphorylated cytoplasmic
inclusions, while WT TDP-43 formed insoluble nuclear foci
that were not phosphorylated (Fig. 4a). Quantification of these
results indicated that cytoplasmic TDP-43 showed a slightly
increased propensity to undergo stress-induced re-localization
and aggregation compared with WT nuclear TDP-43 (Fig. 4b).
Therefore, either oxidative stress or TDP-43 acetylation is capable
of promoting TDP-43 aggregation and loss of function (Figs 2b
and 4b), suggesting a common signalling pathway in which
oxidative stress could mediate TDP-43 acetylation and
subsequent aggregation.
To investigate this possibility, biochemical analysis showed
that insoluble TDP-43-DNLS aggregates became increasingly












































































































































Figure 3 | TDP-43 acetylation impairs RNA-regulatory functions. (a) Recombinant full-length wild-type TDP-43, non-mimic TDP-2KR and acetylation
mimic TDP-2KQ mutants were purified by a sequential extraction according to the methods, and co-purifying nucleic acid was quantified by measuring
absorbance at 260/280nm (A260/280). The percent co-purifying nucleic acid is estimated based on known A260/280 values, which are significantly
reduced for TDP-2KQ and 4CS mutant proteins11, indicating reduced association of these proteins with total extracted nucleic acids. (b) Cells expressing
vector control, TDP-43shRNA, wild-type TDP-43, TDP-K145Q or RNA-binding-deficient 4FL plasmids were co-transfected with a CFTR minigene.
TDP-43 protein levels were determined by immunoblotting, and spliced/unspliced CFTR transcripts were assessed by RT–PCR using specific primers
flanking exon 9. (c) RT–PCR products were quantified using the Agilent 2100 Bioanalyzer and relative values of CFTR transcripts are represented as a log
ratio of spliced/unspliced products. All samples are normalized to the vector control. Splicing analysis was performed using three independent experiments
(N¼ 3), and error is displayed as s.e.m. (d) Crosslinking immunoprecipitation (CLIP) assay was performed on cells expressing wild-type TDP-43, K145Q,
2KQ (K145/192Q) or TDP-4FL plasmids. TDP-43-bound RNAs were immunoprecipitated using anti-myc (9E10), end-labelled with [32P]-ATP and
visualized using bis-tris gel immunoblotting followed by phosphorimaging analysis. Shown is a representative image containing duplicate samples for
each construct that was obtained from N¼ 3 independent experiments. (e) TDP-43-associated RNAs were quantified using TYPHOON software and
normalized to total TDP-43 protein inputs, as determined by immunoblotting with an anti-myc antibody shown in d. All mutants analysed (K145Q,
K145Q/192Q, 4FL) showed significant reduction in RNA-binding compared with WT as assessed by Student’s t-test (P-value r0.01) from N¼ 3
independent experiments. Error bars indicate s.d. of normalized intensity signals derived from experimental replicates.
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arsenite stress (Fig. 4c, lanes 3–4 and Supplementary Fig. 9). To
assess whether stress-induced TDP-43 acetylation could occur in
the absence of ectopically expressed CBP acetyltransferase, we
generated a site-specific acetylated TDP-43 antibody against
Lys-145 to increase the specificity and detection sensitivity for
acetylated TDP-43 (referred to as Ac-K145, see Supplementary
Fig. 10 for antibody characterization). Ac-K145 did not reliably
detect acetylated TDP-43 by direct immunoblot analysis of
insoluble lysates; however, we found that Ac-K145 immunopre-
cipitated acetylated TDP-43 from insoluble fractions of arsenite-
treated cells, and was then detected by immunoblotting with total
TDP-43 antibodies (Fig. 4d, lane 2 and Supplementary Fig. 11).
To assess the aggregation propensity of a non-acetylated mutant
at Lys-145 and Lys-192 (TDP-43-DNLS-2KR) in response to
arsenite stress, a time-course analysis of TDP-43 aggregation was
performed, which showed a delay in the progressive accumulation
of phosphorylated TDP-43 species (P-409/410) B1 h after
arsenite exposure (Fig. 4e, lanes 5–6, and Supplementary
Fig. 11), suggesting acetylation at these specific lysines could
contribute to stress-induced maturation of TDP-43 aggregates.
Thus, potent oxidative stressors can act as environmental signals
to induce acetylation, aggregation and loss of critical TDP-43
functions.
HDAC6 interacts with and deacetylates TDP-43. As our data
suggest that acetylation promotes TDP-43 aggregation, we sought
to identify a TDP-43 deacetylase capable of regulating this
process. One potential candidate is the cytoplasmic deacetylase
HDAC6, previously implicated in the clearance of misfolded
protein aggregates in several neurodegenerative diseases48–57.
A more recent study demonstrated a direct physical interaction
between HDAC6 and TDP-43 in vivo58. Therefore, we evaluated
































































































Figure 4 | Oxidative stress promotes TDP-43 acetylation and pathological TDP-43 aggregation. (a) Double-labelling immunofluorescence microscopy
of WT TDP-43 or cytoplasmic TDP-43 was performed using anti-myc and anti-phospho-TDP-43 (P-409/410) antibodies, which illustrate TDP-43
phosphorylation and aggregation on acute exposure to 0.2mM arsenite for 1 h. Scale bar, 25mm. (b) Quantification of nuclear or cytoplasmic TDP-43
stippling and aggregation phenotypes for all lysine mutants was performed from N¼ 3 independent experiments as detailed in the Methods section. Error
bars represent s.e.m. (c) Immunoblotting of soluble and insoluble fractions using anti-myc and anti-acetyl-lysine antibodies illustrates the accumulation of
acetylated TDP-43 on co-transfection of CBP and exposure to 0.2mM arsenite for 1 h. (d) Immunoprecipitation reaction using Ac-K145 followed by
immunoblotting with a monoclonal anti-TDP-43 antibody allowed increased sensitivity for detection of acetylated TDP-43 in the absence of CBP (see also
Supplementary Fig. 11). (e) Immunoblotting analysis of TDP-43-DNLS and the double lysine mutant, TDP-43-DNLS-2KR, was evaluated in an arsenite-
induced aggregation time-course, which showed delayed accumulation of phosphorylated TDP-43-DNLS-2KR aggregates compared with TDP-43-DNLS.
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Co-expression of WT HDAC6, but not a catalytically inactive
H803A mutant, together with CBP was sufficient to deacetylate
cytoplasmic TDP-43 under normal cellular conditions (Fig. 5a,
lanes 2–4 and Supplementary Fig. 12). Moreover, co-
immunoprecipitation experiments revealed an interaction
between cytoplasmic TDP-43 and HDAC6 that was enhanced
on exposure to arsenite stress, but not a less potent oxidative
stress induced by hydrogen peroxide (Fig. 5b and Supplementary
Fig. 13). The arsenite-induced TDP-43–HDAC6 interaction was
rather unexpected, as HDAC6 recruitment during arsenite
exposure was not sufficient to promote TDP-43 deacetylation
(see Fig. 4c,d), suggesting an inability of cytoplasmic TDP-43
aggregates to become efficiently deacetylated by HDAC6.
Confirming HDAC6 recruitment to TDP-43 aggregates, both
acetylation-mimic (TDP-43-DNLS-K145Q) and arsenite-induced
acetylated TDP-43 aggregates physically interacted with HDAC6
by co-immunoprecipitation assays (Fig. 5c, lanes 2–4 and
Supplementary Fig. 13) and also co-localized with ectopically
expressed or endogenous HDAC6 protein (Fig. 5d). Notably,
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Figure 5 | The deacetylase HDAC6 binds and deacetylates TDP-43 in a stress-regulated manner. (a) Cells were co-transfected with TDP-43-DNLS, CBP,
and either wild-type HDAC6 or the catalytically dead HDAC6-H611A mutant and TDP-43 acetylation was determined by immunoblotting with acetyl-lysine
antibodies similar to Fig. 1c. (b) Cells transfected with myc-tagged TDP-43-DNLS and FLAG-tagged HDAC6 were analysed by co-immunoprecipitation
reactions under basal or stimulated conditions in the presence of 0.1mM arsenite or 1mM peroxide stress for 2 h. Input, representing 5% of total lysate
volume, was analysed by immunoblotting using the indicated antibodies. (c) Co-immunoprecipitation analysis using either TDP-43-DNLS or acetylation
mimic mutants (TDP-43-K145Q or TDP-43-DNLS-K145Q) and wild-type HDAC6 was performed in the absence or presence of arsenite, and
immunoprecipitated proteins were analysed by western blotting with the indicated antibodies similar to b above. (d) Immunofluorescence microscopy was
performed on cells expressing myc-tagged TDP-43-DNLS, acetylation mimic TDP-43-DNLS-K145Q and HDAC6-FLAG where indicated, using anti-FLAG or
endogenous HDAC6 antibodies. TDP-43 acetylation-mimic mutations or acute treatment with arsenite led to the formation of cytoplasmic aggregates that
co-localized with HDAC6. Scale bar, 25mm. (e) Protein levels of the HDAC6/CHIP/Hsp70 complex were determined by western analysis of soluble and
insoluble fractions using HDAC6, CHIP, Hsp70 and Hsp40 specific antibodies. Note, CHIP dimers (arrowhead) suggest activation of CHIP E3 ligase
function, as previously reported68. (f) Depletion of HDAC6 was performed using a specific HDAC6 siRNA followed by arsenite treatment, and solubility
of TDP-43-DNLS and TDP-43-DNLS-2KR proteins was analysed by immunoblotting with total and phosphorylated TDP-43 antibodies. HDAC6 siRNA
knockdown efficiency was validated by assessing total levels of HDAC6 and its major substrate acetylated tubulin.
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CHIP/Hsp70 complex (Fig. 5e and Supplementary Figs 14 and
15), previously implicated together with HDAC6 in the targeted
clearance of the microtubule-associated tau protein48,59,60.
These results suggested that HDAC6-mediated deacetylation of
TDP-43 may represent a homeostatic response to alleviate the
burden of TDP-43 aggregates. To address this possibility, we
analysed arsenite-induced aggregation of cytoplasmic TDP-43 in
the absence of HDAC6 using siRNA-mediated gene silencing.
HDAC6 siRNA led to an increase in arsenite-stimulated TDP-43-
DNLS aggregation, which was reflected by an increase in both
total TDP-43 as well as phosphorylated TDP-43 recovered in
insoluble fractions (Fig. 5f, compare lanes 2–3 with lanes 5–6 and
Supplementary Fig. 16). Importantly, the effect of HDAC6 on
insoluble TDP-43 accumulation was dependent on Lys-145 and
Lys-192 acetylation sites, as loss of HDAC6 did not promote
comparable aggregation of a TDP-43-DNLS-2KR mutant lacking
those critical lysine residues (Fig. 5f, compare lanes 8–9 with lanes
11–12). Taken together, these data suggest that, although HDAC6
can deacetylate TDP-43 under basal conditions, exposure to
oxidative stress promotes the formation of TDP-43 aggregates
that are not effectively deacetylated and thereby accumulate as
mature aggregated TDP-43 species.
Acetylated TDP-43 inclusions are linked to ALS. To investigate
TDP-43 acetylation in human TDP-43 proteinopathies, immu-
nohistochemistry (IHC) was performed on human brain and
spinal cord tissues from subjects with frontotemporal dementia
with TDP-43 pathology (FTLD-TDP) and ALS (see Table 1 for
case demographics), both of which are characterized by robust
TDP-43 pathology. As expected, the FTLD-TDP brain contained
strongly P-409/410-immunoreactive TDP-43 inclusions (Fig. 6a),
which were not readily detectable with an Ac-K145 antibody
(Fig. 6b and Table 1), indicating a lack of TDP-43 acetylation at
Lys-145 in FTLD-TDP. However, given that pathological TDP-43
species in FTLD-TDP were shown to consist predominantly of
C-terminal truncated fragments beginning with residue Arg-208
(ref. 40), we speculated that TDP-43 fragmentation in the FTLD-
TDP brain would preclude the detection of TDP-43 acetylation
on Lys-145 as this residue is not present in the cleaved
pathological TDP-43 fragment.
To further examine Lys-145 acetylation in TDP-43 proteino-
pathies, we analysed the ALS spinal cord, which, in contrast to
FTLD-TDP, harbours significant TDP-43 pathology that consists
predominantly of full-length TDP-43, as both N- and C-terminal
TDP-43 antibodies are capable of detecting TDP-43 inclusions in
ALS motor neurons28. Therefore, pathological TDP-43 species in
the ALS spinal cord should contain the targeted Lys-145
acetylation site. Using serial spinal cord sections from ALS
patients, we detected robust P-409/410 immunoreactive
inclusions (Fig. 6, panels c and e), and most of the
phosphorylated TDP-43 lesions also showed significant skein-
like Ac-K145 immunoreactivity (Fig. 6, panels d and f, and
Table 1). To confirm that Ac-K145 detected TDP-43-positive
inclusions in the ALS spinal cord, double-labelling
immunofluorescence revealed substantial co-localization of
acetylated TDP-43 (Ac-K145) with total TDP-43, as detected
with a human-specific monoclonal TDP-43 antibody (Fig. 6,
panels g–i). These results reveal that acetylated TDP-43 is a
pathological feature associated with full-length, phosphorylated
TDP-43 lesions in the ALS spinal cord but not the FTLD-TDP
brain and support acetylation-induced loss of TDP-43 function
and aggregation as a potential pathogenic mechanism in ALS and
possibly other TDP-43 proteinopathies.
Discussion
In this study, we have identified TDP-43 acetylation as a novel
post-translational modification regulating TDP-43 functional and
biochemical properties. Although WT nuclear TDP-43 is also
subject to acetylation, we found increased cytoplasmic TDP-43
acetylation, possibly due to enhanced lysine accessibility or
conformational differences between nuclear and cytoplasmic
TDP-43. Given that TDP-43 primarily forms cytoplasmic
inclusions in the diseased brain and spinal cord, we speculate
that increased acetylation in the cytoplasm could be responsible,
in part, for inclusion formation in TDP-43 proteinopathies.
Indeed, using an acetylation-specific antibody (Ac-K145), we
detected acetylated TDP-43 pathology in the ALS spinal cord,
suggesting TDP-43 acetylation is linked to ALS pathogenesis
(Fig. 6). Supporting a pathological role, acetylation at Lys-145 was
sufficient to increase TDP-43 pathogenicity in cells, as deter-
mined by both nuclear and cytoplasmic TDP-43 aggregation,
increased C-terminal TDP-43 phosphorylation and loss of
normal nuclear TDP-43 function. Thus, we propose that aberrant
TDP-43 acetylation can act in a pathogenic manner to trigger
aggregation and loss of TDP-43 function (see Fig. 7 model).
Future studies are required to determine whether TDP-43
acetylation is limited to ALS or whether this modification occurs
in a range of other TDP-43 proteinopathies, potentially expand-
ing the clinical and therapeutic relevance of this finding.
To elucidate possible physiological consequences of acetylation
as it relates to normal TDP-43 biology, we investigated nucleo-
cytoplasmic shuttling, TDP-43 protein stability and TDP-43
association with target RNAs. Immunofluorescence experiments
demonstrated that acetylation did not significantly alter TDP-43
nucleo-cytoplasmic shuttling, as acetylated TDP-43 was retained
in its respective subcellular compartments, albeit with altered
Table 1 | Demographics of human FTLD-TDP and ALS cases used in this study.
case # Diagnosis Sex Age at Death PMI (hr) P-409/410 pathology Ac-K145 pathology
1 Normal Female 51 16  
2 Normal Male 90 6  
3 ALS Male 39 5 þ þ þ þ þ
4 ALS Male 56 11.5 þ þ þ
5 ALS Male 57 4 þ þ þ þ þ
6 ALS Female 55 6 þ þ þ þ þ
7 ALS Female 53 24 þ þ þ þ þ
8 ALS Female 81 10 þ þ þ
9 FTLD-TDP Male 54 18 þ þ 
10 FTLD-TDP Female 63 17 þ þ 
11 FTLD-TDP Female 75 13.5 þ þ 
PMI¼ postmortem intervals. ( )¼ no pathology; (þ )¼ rare occurrence of Ac-K145 or P-409/410 pathology; (þ þ )¼moderate occurrence of Ac-K145 or P-409/410 pathology; (þ þ þ )¼more
frequent occurrence of Ac-K145 or P-409/410 pathology. Cases listed here were used for IHC analyses.
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morphology as discrete nuclear foci and cytoplasmic aggregates
(Fig. 2a). Acetylation also did not significantly alter steady–state
TDP-43 protein levels in our cell-based system, suggesting a
minimal effect of acetylation on TDP-43 half-life. This is in
contrast to acetylation-induced protein degradation observed
with the Huntingtin (Htt) protein61. Finally, we evaluated
whether acetylation altered association with target mRNAs, as
our mass spectrometry data identified acetylation on Lys-145 and
Lys-192 within the RRM domains of TDP-43 (Fig. 1g,h). Indeed,
our results suggest that a single acetylation event is sufficient to
impair RNA binding and splicing function (Fig. 3), implicating
Lys-145 as a critical determinant of TDP-43 function. These data
are consistent with a recent study showing that non-specific
chemical acetylation of Lys-145 in vitro using acetic anhydride
occurred most efficiently in the absence of RNA, suggesting
that RNA binding protects Lys-145 from acetylation46. Taken
together, we conclude that TDP-43 acetylation within the RRMs
is sufficient to impair normal RNA binding (Fig. 7, step 2),
thereby providing a rapid and efficient regulatory switch to
modulate TDP-43 association with downstream target RNAs.
Our previous study demonstrated that TDP-43 is subject to
redox regulation, in which oxidative stress promotes TDP-43
cysteine oxidation and disulfide crosslinking, which prevents
RNA binding and splicing function11. As our current study
showed that oxidative stress also promotes TDP-43 acetylation, it
is conceivable that cysteine oxidation and lysine acetylation
represent two critical modifications that coordinately regulate
TDP-43 function under stress conditions, although the temporal
sequence of these modifications still remains unclear. However, as














Figure 6 | TDP-43 acetylation is a pathological feature of ALS but not FTLD-TDP. (a–f) Immunohistochemistry (IHC) was performed on cortical brain
and spinal cord sections from frontotemporal dementia (FTLD-TDP) and ALS cases that harbour abundant TDP-43 pathology. Shown are representative
images of TDP-43 inclusions detected with phosphorylated (P-409/410) and acetylated (Ac-K145) TDP-43 antibodies. FTLD-TDP inclusions showed
characteristic phosphorylated TDP-43 immunoreactivity with P-409/410 (a), which was not detected with Ac-K145 (b). Serial ALS spinal cord sections
analysed by IHC identified TDP-43 inclusions that were immunoreactive with both P409/410 (c,e) and Ac-K145 antibodies (d,f), indicating acetylation of
TDP-43 in ALS spinal cord lesions. See Table 1 for a summary of P-409/410 and Ac-K145 immunoreactivity and details of ALS cases used in this study.
(g–i) Double-labelling immunofluorescence was performed on ALS spinal cord sections using monoclonal anti-TDP-43 (panel g, red) and Ac-K145
(panel h, green) antibodies. The merged image (panel i) highlights the co-localization observed between total TDP-43 and acetylated TDP-43. Scale
bar, 50mm (panels a–d) and 10 mm (panels e,f and g–i).
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oxidation and partial loss of RNA binding could initially provide
increased accessibility for subsequent lysine acetylation within the
RRMs and would support a ‘multiple hit’ model previously
suggested for TDP-43 pathogenesis2,11. Once disengaged from
its targets, TDP-43 likely assumes an inherently unstable
conformation that is highly aggregation-prone11,62,63, and
therefore we hypothesized that acetylation alone would be
sufficient to trigger loss of RNA binding and increased
aggregation propensity. Indeed, acetylation conferred by the
acetyltransferase CBP or acetylation-mimic mutations was
sufficient to induce loss of RNA binding and the accumulation
of insoluble and phosphorylated TDP-43 (Fig. 2). Future studies
are required to elucidate the cross-talk among multiple TDP-43
modifications (cysteine oxidation, acetylation, phosphorylation,
ubiquitination and C-terminal cleavage) and their individual
contributions to TDP-43 function and aggregation. Regardless of
the detailed sequence of events, our results reveal that a complex
post-translational signalling cascade is likely involved in TDP-43
pathogenesis.
Cellular defense mechanisms exist to re-fold or clear
potentially toxic aggregated species, which, if defective, may
contribute to the pathogenesis of ALS64,65. We speculate that
elevated deacetylase activity may act in this regard to reduce
TDP-43 aggregation, and thereby maintain active TDP-43 that is
essential for cell survival. As a recent study identified a physical
interaction between TDP-43, HDAC6, and Parkin in vivo that
may regulate TDP-43 cytoplasmic accumulation58, we focused on
HDAC6 as one potential regulator of TDP-43 acetylation and
aggregation. Interestingly, while HDAC6 was sufficient to
deacetylate soluble cytoplasmic TDP-43, we observed that
cytoplasmic TDP-43 aggregates were unable to be efficiently
deacetylated, possibly due to limited accessibility to lysines that
are buried within the RRM-containing aggregates. Thus, an
inability of HDAC6 and related quality control machinery to
effectively deacetylate TDP-43 could lead to increased TDP-43
aggregation and contribute, in part, to disease pathogenesis
similar to that proposed for abnormal tau acetylation in
Alzheimer’s disease31,33–35. In support of this pathogenic
mechanism, loss of HDAC6 exacerbated TDP-43 aggregation
and led to an increase in insoluble and phosphorylated TDP-43
(Fig. 5f). Conversely, we predict that future approaches to reduce
levels of acetylated TDP-43, for example by pharmacologically
targeting putative TDP-43 acetyltransferase(s), might allow
increased RNA binding and enhancement of critical TDP-43
nuclear functions (Fig. 7, step 6). Overall, the identification of a
reversible TDP-43 acetylation switch provides a novel framework
to further understand both physiological and pathological TDP-
43 functions, which could lead to targeted therapies against ALS
and related TDP-43 proteinopathies.
Methods
Plasmids and cell culture. Human TDP-43 was cloned into pCDNA5/TO vector
(Invitrogen) and site-directed mutagenesis (Quikchange kit; Stratagene) was used
to create K-Q or K-R mutations at residues K145 and K192 as indicated.
Creb-binding protein (CBP) plasmids as well as WT-HDAC6 and HDAC6-H803A
enzyme-inactive mutant expression plasmids were kindly provided by Dr Tso-Pang
Yao (Duke University). Plasmids were transfected into QBI-293 cells (MP Bio-
medicals) using Fugene 6 (Roche) per manufacturer’s instructions. HDAC6 siRNA
(Invitrogen) sequence was as follows: 50-AAAGUUGGAACUCUCACGGUGC
AGC-30 and was transfected using RNAi Max reagent (Invitrogen) following the
manufacturer’s protocols. For oxidative stress treatments, confluent QBI-293 cells
grown in six-well or 10cm dishes were exposed to 50 mM sodium arsenite or 1mM
hydrogen peroxide for 1–12 h, as indicated in text. Cells were harvested and
analysed by western blotting using the indicated antibodies, as detailed below.
Mouse Neuro2A neuroblastoma cells (ATCC) were transfected using Fugene 6
with nNLS, nNLS-K145Q and nNLS-2KQ plasmids and differentiated by 24 h
withdrawal of fetal bovine serum (FBS), which promotes extension of neuritic













































































Figure 7 | Model for reversible regulation of TDP-43 via lysine acetylation. TDP-43 binds with high affinity to nucleic acids under normal cellular
conditions (step 1). Oxidative stress and potentially other environmental or genetic insults promote cysteine disulfide crosslinking11 and lysine acetylation
(this study), which abrogate binding to TDP-43 target RNAs leading to the accumulation of unbound TDP-43 in the nucleus and cytoplasm (step 2).
Free unbound TDP-43 is susceptible to lysine acetylation within the RNA-binding domain on Lys-145 and Lys-192, which prevents TDP-43 association
with target RNAs and promotes TDP-43 aggregation most readily in the cytoplasmic compartment (Fig. 2). Acetylated TDP-43 aggregates are readily
engaged by an HDAC6/CHIP/Hsp70 complex (step 3) that is capable of deacetylating TDP-43 under normal conditions (step 4), but not during sustained
exposure to potent oxidative stimuli (step 5), the latter of which favours the formation of pathological full-length and acetylated TDP-43 lesions
that are detectable in the ALS spinal cord (Fig. 6). TDP-43 deacetylation conversely would result in engagement of TDP-43 mRNA targets, stabilization
of TDP-43 conformation, and re-establishment of normal TDP-43 function as an active RNA regulatory protein (step 6, return to step 1).
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Splicing assay. TDP-43 functional activity was assessed using a tandem trans-
fection CFTR splicing assay. Either control (pcDNA-5TO vector), TDP-43 shRNA
construct (Origene), wild-type (WT) TDP-43, TDP-K145Q or TDP-4FL mutants
were transiently transfected into QBI-293 cells using Lipofectamine 2000 reagent
(Invitrogen) following the standard manufacturer’s protocols. After 48 h, a hybrid
minigene construct TG(13)T(5) (a generous gift from Dr F Baralle, International
Centre for Genetic Engineering and Biotechnology, Trieste, Italy), which monitors
CFTR exon 9 splicing, was transiently transfected into the same cells. Twenty-four
hours after minigene transfection, cells were harvested, and CFTR exon 9 inclusion
versus exclusion in the presence of the indicated TDP-43 plasmids was then
evaluated by RT–PCR from isolated total RNA prepared from cells 72 h after
transfection of TDP-43 constructs and 24 h after transfection of the TG(13)T(5)
CFTR minigene reporter construct. The RT-PCR primers were as follows: Bra2,
50-TAGGATCCGGTCACCAGGAAGTTGGTTAAATCA-30; a2–3, 50-CAACTTC
AAGCTCCTAAGCCACTGC-30 . PCR conditions were as follows: 95 C for 10min
(hot start), followed by 30 cycles of denaturing at 95 C for 30 s, annealing at 57 C
for 30 s and elongation at 72 C for 60 s. PCR products were visualized on a 1.5%
agarose gel and Exon 9 splice products were quantified using the Agilent 2100
Bioanalyzer on a DNA 1000 chip and values were calculated as log ratios of
spliced/unspliced products.
Crosslinking immunoprecipitation assay. Cell-based crosslinking immunopre-
cipitation (CLIP) assay was performed similar to that described66,67 with minor
variations. Transfected QBI-293 cells grown in a 10-cm dish were UV irradiated
twice consecutively in 5ml cold PBS at 400mJ cm 2. Cells were pelleted and
stored at  80 until use. Cell pellets were lysed in NP-40 lysis buffer (50mM Tris-
HCL, pH 7.5; 150mM NaCl, 0.5% NP-40, 50mM NaF containing RNAsin
(Promega) and incubated 10min on ice followed by addition of RQ1 DNase
(Promega, M6101; 30 U) to each tube and incubated at 37 C for 5min. RNase A
(USB #70194Y) was added at 1:5,000 dilution and incubated at 37 C for 5min,
followed by ultra-centrifugation with polycarbonate tubes at 30,000 r.p.m. for
20min at 4 C. The supernatant containing TDP-43 bound RNAs was mixed with
protein A/G beads (Santa Cruz) and 5 mg anti-myc 9E10 antibody (Santa Cruz) and
rotated 3–4 h 4 C. Beads were washed as follows: two times with ice-cold NP-40
lysis buffer, two times with buffer B [5 PBS (no Mg2þ , no Ca2þ ), 0.5% NP-40]
and two times with buffer C (50mM Tris–Cl, pH 7.4, 10mM MgCl2, 0.5% NP-40).
TDP-43 bound A/G beads were then treated with Calf-Intestinal Alkaline
Phosphatase (NEB) in the presence of RNAs according to the manufacturer’s
protocol. Samples were washed once with Buffer C (see above), once with Buffer D
(50mM Tris-HCL, pH 7.5; 20mM EGTA; 0.5% NP-40) and then twice with Buffer
C. RNAs were end-labelled using [32P]- g- ATP (Perkin Elmer, BLU002A) and T4
PNK enzyme (NEB, T4 polynucleotide kinase, M0201L) followed by bead washes:
once with NP-40 lysis buffer, twice with Buffer B and five times with buffer C.
Samples were loaded onto 10% Bis-Tris gels (Bio-Rad) using an MOPS running
buffer system, transferred onto nitrocellulose membranes and signals were
quantified as pixel intensities using a TYPHOON phosphorimager system and
normalized to WT TDP-43 bound RNAs.
Recombinant TDP-43 methods. TDP-43 recombinant proteins (WT, K145/
192Q, K145/192R) were purified from BL-21 cells using the pCOLD vector
expression system (Takara Bio). After protein induction, all TDP-43 proteins were
present predominantly in insoluble fractions of bacterial lysates. To generate
soluble-purified TDP-43 protein, bacterial pellets were washed extensively 5 in
RIPA buffer to remove soluble proteins, and insoluble pellets containing TDP-43
proteins were subsequently extracted repeatedly in 0.1% SDS, 0.1M MOPS pH 7.5
and TDP-43 solubility was monitored until total protein was solubilized.
Re-solubilized TDP-43 proteins were estimated to be B95% pure based on
visualization by Coomassie staining. Protein stocks were maintained at high
concentration (10mgml 1) in 0.1% SDS, 0.1M MOPS pH 7.5 to prevent loss of
TDP-43 solubility. We note that TDP-2KQ mutant protein required repetitive
extractions in 0.1% SDS, 0.1M MOPS pH 7.5 to re-solubilize the protein, indi-
cating reduced solubility due to impaired binding to nucleic acids.
Peptide/antibody generation. Polyclonal anti-acetyl TDP-43 (K145) antibodies
were generated using the acetylated TDP-43 peptide GHSKGFG-C containing
K145 acetylation which was used to immunize rabbits (Pocono Rabbit Farm and
Laboratory, Canadensis, PA). Double affinity purification was performed using
native and acetylated peptides sequentially using Sulfolink columns (Pierce Bio-
technology). Site specificity of Ac-K145 was confirmed in vitro by western blot
analysis of purified WT and lysine mutant proteins (see above) and by peptide
ELISA assays using acetylated and unmodified peptides (Supplementary Fig. 10).
Biochemical methods and co-immunoprecipitation analysis. Fractionation of
all cell lysates was performed by sequential extraction using buffers of increasing
strength. Cells from six-well culture dishes were scraped into 300ml RIPA buffer
(50mM Tris pH 8.0, 150mM NaCl, 1%NP-40, 5mM EDTA, 0.5% sodium deox-
ycholate, 0.1%SDS) containing 1mM phenylmethylsulfonyl fluoride, a mixture
of protease inhibitors (1mgml 1 pepstatin, leuptin, N-p-Tosyl-L-phenylalanine
chloromethyl ketone, Na-Tosyl-L-lysine chloromethyl ketone hydrochloride,
trypsin inhibitor; Sigma) and a mixture of phosphatase inhibitors (2 mm imidazole,
1 mm NaF, 1 mm sodium orthovanadate; Sigma). Samples were sonicated and
centrifuged at 100,000g for 30min at 4 C, and then re-extracted in RIPA buffer to
ensure complete removal of soluble proteins. Resultant insoluble pellets were
extracted in urea buffer (7M urea, 2M Thiourea, 4%CHAPS, 30mM Tris, pH 8.5),
sonicated and centrifuged at 100,000 g for 30min at room temperature. Soluble
and insoluble fractions were analysed by western blotting using the indicated
antibodies. Antibodies for western analysis were as follows: rabbit polyclonal
anti-TDP-43 (Proteintech) 1:1,000, mouse monoclonal antibody anti-TDP-43
(Proteintech) 1:1,000, rabbit polyclonal anti-TDP-43 C-terminal 1038 1:10,000,
rabbit polyclonal anti-TDP-43 N-terminal 1065 1:10,000, anti-GAPDH (6C5
mouse mAb; Advanced ImmunoChemical) 1:3,000, anti-acetylated tubulin (Sigma)
1:1,000, anti-a-tubulin (Sigma) 1:1,000, anti-HDAC6 (H-300; Santa Cruz) 1:1,000,
anti-acetyl-lysine (1:1,000, Cell Signalling), polyclonal anti-CHIP (1:1,000, Sigma).
For insoluble Ac-K145 immunoprecipitation reactions, urea solubilized fractions
were diluted tenfold in Triton buffer (1% Triton-X-100, 40mM Tris pH 8.0) before
immunopreciptation reactions using 10 mg of Ac-K145 antibody conjugated to
protein A/G beads, followed by extensive washes and western blotting using a
monoclonal TDP-43 antibody (Proteintech). For co-immunoprecipitation studies,
QBI-293 cells were lysed in NP-40 lysis buffer referred to as NETN buffer (50mM
Tris-Cl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 1mM sodium orthova-
nadate, 1mM sodium fluoride, 1mM PMSF, 0.2mM leupeptin, protease inhibitor
cocktail). Soluble supernatants (1mg total protein) were cleared by centrifugation,
incubated overnight with protein A/G beads (Santa Cruz) complexed to the
indicated antibodies described in the figure legends, and subsequently analysed by
SDS–PAGE and immunoblotting.
Immunoprecipitation and mass spectrometry analysis. For cell-based mass
spectrometry (MS) analysis, 10-cm dishes of QBI-293 cells were transiently
transfected with TDP-43-DNLS and CBP plasmids. Total lysates were prepared and
TDP-43 was immunoprecipitated from these fractions using anti-TDP-43 (clone
171) complexed to protein A/G beads (Sigma). Immunoprecipitated samples were
analysed by SDS–PAGE electrophoresis in the presence of reducing agents and
analysed by Coomassie staining and gel excision followed by nanoLC/nanospray/
MS/MS. The analysis was performed using the University of Pennsylvania pro-
teomics core facility and data were acquired with Xcalibur 2.0 (ThermoFisher) and
analysed with PEAKS 6.0 (Bioinformatics Solutions) and Scaffold 3 (Proteome
Software) software packages. Cutoffs: peptide P-value o95%; protein P-value
o99.0%.
Immunocytochemistry and quantification. Cultured cells were fixed in 4%
paraformaldehyde (PFA) for 10min, rinsed three times in PBS and permeabilized
with 0.2% Triton X-100 (Sigma) in PBS for 10min. Cells were then blocked in 5%
milk for 1 h and subsequently incubated with primary antibodies of interest
overnight at 4 C following standard immunofluorescence techniques. Cell-based
nuclear stippling and cytoplasmic aggregation of lysine mutants was performed by
immunofluorescence microscopy ( 40 magnification) using an Olympus BX 51
microscope. Stippling and aggregation phenotypes were quantified as a percent of
transfected cells using 410 fields, and sampling error was calculated using the
s.e.m. Statistical analysis was determined using a two-tailed unpaired t-test with
unequal variance (significance set at P-values o0.05). All quantitative fluorescence
was independently validated with a minimum of N¼ 3 biological replicates.
Primary antibodies used for immunofluorescence were as follows: polyclonal anti-
TDP-43 (Proteintech, 1:500), polyclonal anti-myc (1:4,000, Sigma), monoclonal
anti-myc 9E10 (Sigma, 1:1,000), monoclonal anti-Hsp70 (Stressgen, 1:500).
Immunohistochemistry and double labelling. For human studies, fixed, paraffin-
embedded tissue blocks were obtained from the Center for Neurodegenerative
Disease Research Brain Bank at the University of Pennsylvania. Consent for
autopsy was obtained from legal representatives for all subjects in accordance with
local institutional review board requirements. In brief, fresh tissues from each brain
were fixed with 70% ethanol in 150mM NaCl, infiltrated with paraffin and cut into
6-mm serial sections. Immunohistochemistry (IHC) was performed using the
avidin-biotin complex (ABC) detection system (Vector Laboratories, Burlingame,
CA) and 3,30-diaminobenzidine. In brief, sections were deparaffinized and
rehydrated, antigen retrieval was done by incubating section in 88% formic acid,
endogenous peroxidases were quenched with 5% H2O2 in methanol for 30min and
sections were blocked in 0.1mol l 1 Tris with 2% fetal bovine serum for 5min.
Primary antibodies were incubated for either 1 or 2 h at room temperature or
overnight at 4 C. The following primary antibodies were used for IHC analysis:
AcK145 (this study, 1:500), monoclonal TDP-43 (Proteintech, 1:1,000), P-409/410
(1:500). After washing, sections were sequentially incubated with biotinylated
secondary antibodies for 1 h and avidin–biotin complex for 1 h. Bound antibody
complexes were visualized by incubating sections in a solution containing 100mM
TrisHCl, pH 7.6, 0.1% Triton X-100, 1.4mM diaminobenzidine, 10mM imidazole
and 8.8mM H2O2. Sections were then lightly counterstained with haematoxylin,
dehydrated and coverslipped. We note that IHC analysis of human tissue using
Ac-K145 requires antigen retrieval (formic acid) for maximal detection sensitivity
of TDP-43 inclusions and displays mild cross-reactivity with other nuclear proteins.
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Double-labelling Immunofluorescence- Double-labelling immunofluorescence (IF)
analyses were performed using Alexa Fluor 488- and 594-conjugated secondary
antibodies (Molecular Probes, Eugene, OR). The sections were then treated to
remove autofluorescence with Sudan Black solution for 5min and coverslipped
with Vectashield mounting medium (Vector Laboratories). Digital images were
obtained using an Olympus BX 51 microscope (Tokyo, Japan) equipped with
bright-field and fluorescence light sources using a ProgRes C14 digital camera
(Jenoptik AG, Jena, Germany) and Adobe Photoshop, version 9.0 (Adobe Systems,
San Jose, CA) or digital camera DP71 (Olympus) and DP manager (Olympus).
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